LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.

Targeted testing for hereditary breast and ovarian cancer syndromes

BRCAssure

BRCA1 and BRCA2 mutations account for most families with hereditary breast and ovarian cancer syndrome (HBOC),1 and the estimated lifetime risk of breast cancer in women with BRCA1 mutations is 50% to 80%; for BRCA2, the risk is 40% to 70%.2

At Integrated Genetics, we understand the importance of identifying patients with a BRCA mutation. With the analytical sensitivity and specificity of Integrated Genetics’ BRCAssure assay, and a comprehensive suite of tests to identify BRCA mutations associated with breast and ovarian cancer, you can have confidence in the test performance and select the BRCAssure testing option that is the most appropriate for your patient based on her or his personal or family medical history.

BRCA estimated lifetime cancer risk chart

BRCAssure—Comprehensive BRCA1/2 analysis
Full sequencing of the BRCA1/2 genes, plus deletion/duplication analysis. May be used to assess the risk of carrying a BRCA1/2 mutation when the patient’s history suggests an increased risk for hereditary breast and ovarian cancer in the absence of a known familial mutation. Learn more

BRCAssure—Ashkenazi Jewish panel
Targeted analysis of the founder mutations found within the Ashkenazi Jewish population. May be used as a first line test for individuals of Ashkenazi Jewish descent; if negative the option to run a Comprehensive BRCA1/2 Analysis is available. Learn more

BRCAssure—BRCA1 targeted analysis
Targeted sequencing for specific familial or known mutations on the BRCA1 gene. Learn more

BRCAssure—BRCA2 targeted analysis
Targeted sequencing for specific familial or known mutations on the BRCA2 gene. Learn more

BRCAssure—BRCA1/2 deletion/duplication analysis
May be used to detect the presence of a deletion or duplication in the BRCA1/2 genes after previous sequencing tests were negative and deletion/duplication analysis was not offered or when a specific familial duplication or deletion is known. Learn more

Other testing options

In addition to hereditary cancer screening, we also offer: serum screening and noninvasive prenatal testing (NIPT, sometimes called NIPS or cell-free DNA), including the pioneering whole-genome NIPTcarrier screening, from comprehensive to single-gene; and diagnostic testing that can be used on prenatal and products of conception (POC) samples, as well as pediatric, cord blood or adult samples.


References

  1. American College of Obstetricians and Gynecologists. Hereditary breast and ovarian cancer syndrome. ACOG Practice Bulletin No. 103. Obstet Gynecol. April 2009; 113:957-66. Reaffirmed 2013.
  2. Petrucelli N, Daly MB and Feldman GL. BRCA1 and BRCA2 hereditary breast and ovarian cancer. GeneReviews. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1247. Published September 4, 1998. Updated September 26, 2013. Accessed October 22, 2013.